Navigation Links
AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria
Date:5/27/2009

AMSTERDAM, May 28 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the European Medicines Agency has granted Orphan Drug Designation to AMT's gene therapy product AMT-021 for the treatment of acute intermittent porphyria (AIP).

Orphan Drug Designation for AIP entitles AMT to ten year market exclusivity in Europe following marketing approval for AMT-021 if this product candidate is the first new drug with a major medical benefit receiving marketing approval for the European Union. The designation also provides for special benefits, including research support, eligibility for protocol assistance and possible exemptions or reductions in certain regulatory fees during development or at the time of application for marketing approval.

"We are proud to have received this Orphan Drug Designation for the treatment of acute intermittent porphyria," said Sander van Deventer, Chief Executive Officer of AMT. "This designation is an important step in the development of a treatment for this seriously debilitating and potentially lethal disease."

About Acute Intermittent Porphyria

Acute intermittent porphyria is a rare genetic disease in which mutations in the PBGD gene result in insufficient activity of a protein necessary for the synthesis of heme. This leads to an accumulation of toxic intermediate metabolites resulting in a wide variety of problems including acute, severe abdominal pains, psychiatric, neurologic illnesses, and muscular weakness. Long-term consequences may be irreversible nerve damage, liver cancer and kidney failure. Acute porphyric attacks can be life-threatening.

AIP affects 1 per 10.000 people in the European Union.

Currently available therapies do not prevent the symptoms and consequences of acute porphyric attacks. AMT has demonstrated that its prod
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)...  Astellas today announced topline results from the ... safety of intravenous (IV) and oral isavuconazole, commercially ... adults with candidemia and other invasive Candida ... the trial did not meet its primary endpoint ... patients at the end of IV therapy compared ...
(Date:7/29/2015)... 29, 2015  Unilife Corporation ("Unilife" or the "Company") ... manufacturer and supplier of injectable drug delivery systems, today ... provides the Company with flexibility and control to support ... signed an equity purchase agreement for up to $45 ... Chicago -based institutional investor, which provides ...
(Date:7/29/2015)... , July 29, 2015  According to data ... Services, the 2016 average monthly Medicare Part D premium ... far lower than was originally projected, the Pharmaceutical Care ... D program continues to be a bright spot in ... choices in each region and using cutting edge, cost-saving ...
Breaking Medicine Technology:Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 2Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 3Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 4Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 5Unilife Announces Multifaceted Financing Strategy 2Unilife Announces Multifaceted Financing Strategy 3Unilife Announces Multifaceted Financing Strategy 4Unilife Announces Multifaceted Financing Strategy 5
(Date:7/30/2015)... , ... July 30, 2015 , ... ... Google Partners All-Star at the annual All-Stars Summit. Google Partners is the platform ... agencies may receive the full support and tools necessary to run successful search ...
(Date:7/30/2015)... ... July 30, 2015 , ... Gummy smile surgeon, Dr. Alex ... and surgery, as well as the patented gum depigmentation treatmet. Dr. Farnoosh is a ... with many patients from around the world. , “Like treatment of any other disease ...
(Date:7/30/2015)... ... ... InventHelp, a leading inventor service company, announces that one of ... easy to apply lotion or medication to a hard-to-reach area. This invention is patented. ... medication to the back, and provides thorough coverage. The product would prevent the user ...
(Date:7/30/2015)... ... 30, 2015 , ... After conducting a nationwide executive search led by healthcare ... in Far Rockaway, N.Y., has hired Gerard (Jerry) Walsh as Chief Executive Officer. Walsh ... healthcare leadership experience, Walsh is an expert in organizational change, physician development, implementation of ...
(Date:7/30/2015)... ... July 30, 2015 , ... According to ... not find a complete removable denture acceptable. The demand for dental implants is ... incorporate less expensive, immediate loading techniques will have the ability to offer the ...
Breaking Medicine News(10 mins):Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2Health News:InventHelp® Client Patents “My Back Buddy” – Device Could Apply Lotion to Hard-to-Reach Areas Easily 2Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 2Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 3Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 4Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 5Health News:Chicago Implant Dentist/Implantologist Dr. Irfan Atcha Speaks to Local Dentists about Advances in Dental Implants in August. 2Health News:Chicago Implant Dentist/Implantologist Dr. Irfan Atcha Speaks to Local Dentists about Advances in Dental Implants in August. 3
... to avoid devastating vision injuries, group says , , ... in the United States, about 40,000 people suffer ... Ophthalmology (AAO), which recommends that all athletes wear ... eye-care professional. , Lenses made from polycarbonate materials ...
... may provide protection against heart disease ... and certain cancers, ARLINGTON, ... the recognized ranks of healthful whole grains, according,to an announcement this week ... food labels to bear the whole grain health,claim. This will enable consumers ...
... International,Rescue Committee emergency team members have arrived in ... deployment to the region as the IRC,prepares for ... "Nearly all homes were destroyed in the ... no access to clean drinking water," says the,IRC,s ...
... Facility, CARSON, Calif., May 9 Leiner ... that it has submitted a,proposed agreement with the ... Court in Delaware for approval. The proposed agreement ... and distribution of certain over-the-counter (OTC) drug products ...
... for Iraq and Afghanistan Veterans Gather in Virginia to,Envision ... CHANTILLY, Va., May 9 As the war ... toll climbs above 4,000 and,casualty numbers approach the 30,000 ... on the homefront have organized to help,bereaved families and ...
... of stimulants a fixture of European nightlife, study says , , ... adults in Europe are drinking alcohol and taking drugs for ... people who are regular nightlife-goers. , The results showed ... aged 16 to 35 drink alcohol to increase their chances ...
Cached Medicine News:Health News:Protective Eyewear Key to Sports Safety 2Health News:FDA Approves Health Claim for Brown Rice 2Health News:FDA Approves Health Claim for Brown Rice 3Health News:FDA Approves Health Claim for Brown Rice 4Health News:FDA Approves Health Claim for Brown Rice 5Health News:International Rescue Committee Mobilizes More Emergency Teams for Myanmar; Warns of Massive Health Disaster Unless Aid Reaches Cyclone Survivors Fast 2Health News:Leiner Health Products Submits Proposed Agreement with Department of Justice to U.S. Bankruptcy Court for Approval 2Health News:Leading Veterans Service Organizations Meet Near Washington May 13-15, 2008 2Health News:Leading Veterans Service Organizations Meet Near Washington May 13-15, 2008 3Health News:Leading Veterans Service Organizations Meet Near Washington May 13-15, 2008 4Health News:Young Adults Using Alcohol, Drugs for Better Sex 2
An environmentally-safe, CN-free lytic reagent designed for use on the Abbott CELL-DYN® 1800 three-part differential hematology analyzer....
... Retics is a 5-part differential control that ... Abbott CELL-DYN 3200, 3500, 3700 and 4000 ... nucleated red blood cells that can be ... The assay contains automated and manual reticulocyte ...
... hematology control for the Abbott CELL-DYN 3000, ... for the five-part white cell differential, as ... CELL-DYN 1600 and 1700. Open-vial stability is ... days. Para 12 Plus is packaged in ...
The technology in the LATITUDE system allows your doctor to get the same data from your device whether you are at home or in your doctor's office. This information transfer happens automatically....
Medicine Products: